False-negative MRI biomarkers of tumour response to targeted cancer therapeutics
نویسندگان
چکیده
منابع مشابه
Predicting Targeted Cancer Therapeutics
Motivation: Cancer is a complex and evolving disease, making it difficult to discover effective treatments. Traditional drug discovery relies on high-throughput screening on reductionist models in order to enable the testing of 105 or 106 compounds. These assays lack the complexity of the human disease. Functional assays overcome this limitation by testing drugs on human tumors, however they ca...
متن کاملTargeted cancer therapeutics.
Targeted therapies can be defined as drugs developed against a specific target based on its important biological function in cancer. In contrast, nontargeted therapies are drugs identified by phenotypic screening of natural products or chemical libraries against established cancer cell lines or preclinical animal models without a priori knowledge of the target. Targeted therapies are designed t...
متن کاملUse of Apoptotic Biomarkers to Predict Response to Radiotherapy in Breast Cancer Patients
Introduction: To enhance radiation therapy efficiency it is crucial to implement an individual-based treatment. The aim of present study was to identify the mechanism of intrinsic apoptosis pathway on radiosensitivity and normal tissue complications caused by the radiotherapy. Materials and Methods: radiation-induced apoptosis in periphera...
متن کاملIdentification of Direct Target Engagement Biomarkers for Kinase-Targeted Therapeutics
Pharmacodynamic (PD) biomarkers are an increasingly valuable tool for decision-making and prioritization of lead compounds during preclinical and clinical studies as they link drug-target inhibition in cells with biological activity. They are of particular importance for novel, first-in-class mechanisms, where the ability of a targeted therapeutic to impact disease outcome is often unknown. By ...
متن کاملMechanisms of resistance to ErbB-targeted cancer therapeutics.
The ErbB receptors, such as EGFR, have been intensely pursued as targets for cancer therapeutics. However, a large percentage of patients who are initially responsive to ErbB-targeted therapies experience tumor recurrence and become refractory to therapy. In this issue of the JCI, Guix et al. demonstrate that downregulation of IGF-binding protein 3 (IGFBP-3) and -4, the negative regulators of I...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 2012
ISSN: 0007-0920,1532-1827
DOI: 10.1038/bjc.2012.208